Archives
-
GM 6001 (Galardin) for ECM Research
2026-09-13
GM 6001 (Galardin) gives researchers a broad-spectrum way to perturb MMP-dependent extracellular matrix remodeling across neural, cartilage, cancer, and vascular models. This guide translates its biochemical profile into practical workflows, controls, and troubleshooting strategies while using Alzheimer’s disease perineuronal-net research as a mechanistic case study.
-
RESTRICT-seq Maps Epigenetic Dependencies in SCC Resistance
2026-09-12
The bioRxiv preprint presents RESTRICT-seq as a time-gated CRISPR screening framework for resolving when genetic perturbations influence squamous cell carcinoma resistance. Its main contribution is methodological: temporal control can separate early resistance determinants from dependencies that emerge after resistant states have formed, creating a more precise route to epigenetic target validation.
-
GM 6001 (Galardin) for ECM Research
2026-09-11
GM 6001 (Galardin) provides a practical way to test how MMP-driven matrix remodeling affects perineuronal nets, meniscal repair, EGFR signaling, cancer phenotypes, and vascular injury models. This guide translates its nanomolar biochemical profile into controlled workflows, cross-domain use cases, and troubleshooting decisions.
-
Idoxuridine: Mechanism-Led Antiviral Assay Design
2026-09-11
Idoxuridine is a thymidine-analog antiviral compound for dissecting viral DNA replication. This guide connects molecular mechanism, orthogonal assay design, and lessons from human-neuron pharmacology to improve interpretation beyond simple viability readouts.
-
α-KG Activates LKB1–AMPK in Periodontitis
2026-09-10
This Cellular Signalling study identifies an α-ketoglutarate–LKB1–AMPK axis that restores mitochondrial function and limits inflammation-induced senescence in human periodontal ligament stem cells. Its combined cell and animal evidence links mitochondrial recovery with improved osteogenic capacity and periodontal regeneration, offering a mechanistic framework for stem-cell-based periodontal research.
-
Auranofin Workflows for Redox Cancer Research
2026-09-10
Build reproducible Auranofin experiments around thioredoxin reductase inhibition, oxidative stress modulation, apoptosis, and radiation response. This workflow also connects redox assays with the FOXO3/YAP metabolic framework in hepatocellular carcinoma without overstating what has been directly demonstrated.
-
Ferroptosis, Apoptosis, and BH3-Mimetic Modulation
2026-09-09
The 2025 study shows that ferroptosis and apoptosis can intersect rather than behaving as fully independent death programs. Its central practical message is that BH3-mimetics may enhance or redirect ferroptotic death, but can also suppress it through previously unrecognized antioxidant activity, making pathway-specific validation essential.
-
VDR-Linked Ferroptosis in Salivary Hyposecretion
2026-09-09
A 2025 study identifies vitamin D receptor upregulation as a sex-specific regulator of ferroptosis-related salivary hyposecretion in Sod1-knockout female mice. Its mouse and cell-based experiments connect oxidative stress, VDR-dependent TFRC regulation, and salivary gland dysfunction, providing a mechanistic framework for studying dry mouth associated with aging and redox imbalance.
-
PKM2 inhibitor (compound 3k): Research Workflows
2026-09-08
Build reproducible cancer-metabolism assays around PKM2 inhibitor (compound 3k), from dose-response profiling to glycolytic and autophagy-linked validation. Its preclinical ovarian cancer and macrophage-immunometabolism applications make it useful for both tumor-cell studies and carefully bounded mechanism research.
-
Hepatic sEH, Nrf2, and Osteoporosis
2026-09-08
The reference study identifies a liver–bone axis in osteoporosis in which hepatic soluble epoxide hydrolase alters circulating 14,15-EET and 14,15-DHET, suppressing Nrf2-ARE signaling and promoting osteoclast differentiation. Its combination of clinical samples, ovariectomy-induced osteoporosis, liver-specific sEH knockdown, pharmacological inhibition, and transcriptomics provides a mechanistic framework for studying redox imbalance and bone resorption.
-
RESTRICT-seq Maps KAT6A Dependencies in SCC Resistance
2026-09-07
The RESTRICT-seq preprint introduces a time-gated CRISPR screening strategy for resolving epigenetic dependencies that emerge during squamous cell carcinoma resistance. Its identification of KAT6A links chromatin regulation with resistance biology and provides a rationale for follow-up genetic, senescence, and pharmacological studies.
-
RIP3 Stoichiometry in Necrosome Assembly
2026-09-07
The reference study combines quantitative STORM imaging with mathematical modeling to show that necrosome function depends on an approximately 3:1 RIP3-to-RIP1 stoichiometry rather than unrestricted RIP3 polymerization. Its findings reveal how assembly size, complex abundance, and downstream feedback jointly create a thresholded necroptotic response.
-
Berbamine hydrochloride: NF-κB Inhibitor Workflows
2026-09-05
Build reproducible cytotoxicity, pathway, and ferroptosis-sensitization assays with Berbamine hydrochloride across KU812 and HepG2 models. The workflow separates established product specifications from testable hypotheses inspired by the METTL16-SENP3-LTF axis in hepatocellular carcinoma.
-
BRD4–RAC1 Co-targeting in Breast Cancer
2026-09-04
The reference study identifies combined BRD4 and RAC1 inhibition as a subtype-sensitive strategy that suppresses breast cancer growth, migration, stemness, and xenograft tumorigenesis. Its key mechanistic contribution is linking this combination to disruption of the c-MYC–G9a–FTH1 axis and downregulation of HDAC1-associated histone regulation.
-
BMS-777607 in MET and hiPSC Platelet Assays
2026-09-04
BMS-777607 is a selective c-Met inhibitor with strong preclinical evidence in metastatic tumor models. This article develops a decision framework for using its MET-family pharmacology alongside, but not as a substitute for, optimized hiPSC-derived platelet assays.